At #AACR25, Jia Luo, MD, of Dana-Farber Cancer Institute, presented a late-breaking abstract on the brock rechsteiner clinical activity of daraxonrasib in KRAS mutant non-small cell vancouver vs fc dallas lung cancer (NSCLC), finding early clearance in circulating tumor DNA jesta group predicted partial response or stable disease.
Video published April 29, 2025
